Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries

Evommune is eligible to receive up to $62 million in upfront and milestone payments Expanded collaboration adds additional non-dilutive cash to Evommune’s strong balance sheet PALO ALTO, Calif., March 20, 2024 /PRNewswire/ — Evommune, Inc., a biotechnology company discovering and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks